CL2014001156A1 - Method to reduce the level of uric acid in a subject with impaired renal function by administering a compound of formula (i). - Google Patents
Method to reduce the level of uric acid in a subject with impaired renal function by administering a compound of formula (i).Info
- Publication number
- CL2014001156A1 CL2014001156A1 CL2014001156A CL2014001156A CL2014001156A1 CL 2014001156 A1 CL2014001156 A1 CL 2014001156A1 CL 2014001156 A CL2014001156 A CL 2014001156A CL 2014001156 A CL2014001156 A CL 2014001156A CL 2014001156 A1 CL2014001156 A1 CL 2014001156A1
- Authority
- CL
- Chile
- Prior art keywords
- administering
- subject
- compound
- formula
- level
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/059425 WO2013066352A1 (en) | 2011-11-04 | 2011-11-04 | Methods for treating gout in patient subpopulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014001156A1 true CL2014001156A1 (en) | 2015-01-16 |
Family
ID=48192536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014001156A CL2014001156A1 (en) | 2011-11-04 | 2014-05-02 | Method to reduce the level of uric acid in a subject with impaired renal function by administering a compound of formula (i). |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2775835A4 (en) |
| JP (1) | JP6047172B2 (en) |
| KR (1) | KR101848122B1 (en) |
| CN (1) | CN104066323A (en) |
| AU (1) | AU2011380509B2 (en) |
| BR (1) | BR112014010693A2 (en) |
| CA (1) | CA2859689C (en) |
| CL (1) | CL2014001156A1 (en) |
| IL (1) | IL232385A (en) |
| MX (1) | MX354846B (en) |
| NZ (1) | NZ624714A (en) |
| SG (1) | SG11201402027PA (en) |
| WO (1) | WO2013066352A1 (en) |
| ZA (1) | ZA201403574B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150002799A (en) * | 2012-04-13 | 2015-01-07 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent |
| CN104068288B (en) * | 2014-07-25 | 2016-08-24 | 许伟琦 | A kind of feed additive of anti-lithangiuria |
| CN105920022A (en) * | 2016-05-12 | 2016-09-07 | 成都易创思生物科技有限公司 | Anti-gout medicinal compound preparation |
| WO2019082335A1 (en) * | 2017-10-26 | 2019-05-02 | 大塚製薬株式会社 | Inositol phosphate-containing composition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4250191A (en) * | 1978-11-30 | 1981-02-10 | Edwards K David | Preventing renal failure |
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| CA2706858C (en) * | 2007-11-27 | 2013-12-24 | Ardea Biosciences, Inc. | Imidazole and triazole derivatives and methods of use |
-
2011
- 2011-11-04 KR KR1020147015209A patent/KR101848122B1/en active IP Right Grant
- 2011-11-04 CN CN201180076189.7A patent/CN104066323A/en active Pending
- 2011-11-04 BR BR112014010693-2A patent/BR112014010693A2/en not_active IP Right Cessation
- 2011-11-04 MX MX2014005399A patent/MX354846B/en active IP Right Grant
- 2011-11-04 NZ NZ624714A patent/NZ624714A/en not_active IP Right Cessation
- 2011-11-04 JP JP2014541012A patent/JP6047172B2/en not_active Expired - Fee Related
- 2011-11-04 AU AU2011380509A patent/AU2011380509B2/en not_active Ceased
- 2011-11-04 CA CA2859689A patent/CA2859689C/en not_active Expired - Fee Related
- 2011-11-04 WO PCT/US2011/059425 patent/WO2013066352A1/en active Application Filing
- 2011-11-04 SG SG11201402027PA patent/SG11201402027PA/en unknown
- 2011-11-04 EP EP11875027.2A patent/EP2775835A4/en not_active Withdrawn
-
2014
- 2014-04-30 IL IL232385A patent/IL232385A/en active IP Right Grant
- 2014-05-02 CL CL2014001156A patent/CL2014001156A1/en unknown
- 2014-05-16 ZA ZA2014/03574A patent/ZA201403574B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013066352A1 (en) | 2013-05-10 |
| JP2014532759A (en) | 2014-12-08 |
| CN104066323A (en) | 2014-09-24 |
| JP6047172B2 (en) | 2016-12-21 |
| KR20140123927A (en) | 2014-10-23 |
| EP2775835A4 (en) | 2015-07-29 |
| EP2775835A1 (en) | 2014-09-17 |
| IL232385A0 (en) | 2014-06-30 |
| SG11201402027PA (en) | 2014-09-26 |
| MX354846B (en) | 2018-03-22 |
| AU2011380509A1 (en) | 2014-05-29 |
| IL232385A (en) | 2017-10-31 |
| KR101848122B1 (en) | 2018-04-11 |
| CA2859689A1 (en) | 2013-05-10 |
| ZA201403574B (en) | 2015-11-25 |
| BR112014010693A2 (en) | 2020-11-10 |
| CA2859689C (en) | 2018-05-22 |
| AU2011380509B2 (en) | 2016-05-19 |
| MX2014005399A (en) | 2015-04-08 |
| NZ624714A (en) | 2016-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2685832T3 (en) | STABILIZED HYPOHALOGENIC ACID SOLUTIONS | |
| IL231828A0 (en) | Etanercept formolations stabilized with xylitol | |
| IL227754B (en) | 4-hydroxybutyric acid deuterated analogs | |
| EP2782897A4 (en) | Process to prepare levulinic acid | |
| CL2014002622A1 (en) | A method to modify beta-stucco using diethylene-triamin-pentaacetic acid. | |
| CO6910182A2 (en) | Improved nitric acid production | |
| DK2390914T3 (en) | Arrangement of two connecting partners with a low-temperature-pressure interconnection as well as process for its preparation | |
| EP2682409A4 (en) | Hyaluronic acid derivative modified by amino-carbonic acid | |
| DK2771475T3 (en) | PROCEDURE FOR THE CONVERSION OF LIGNOCELLULOSE TO AN ORGANIC ACID WITH RECYCLING OF DISSOLVED SALTS | |
| DK3351546T3 (en) | LONG-ACTING INJECTABLE MOXIDECT INFORMULATIONS | |
| BR112013031365A2 (en) | method to produce a compound | |
| HK1185947A1 (en) | Use of stathmin as a biomarker of drug response to furazanobenzimidazoles stathmin | |
| CL2014001156A1 (en) | Method to reduce the level of uric acid in a subject with impaired renal function by administering a compound of formula (i). | |
| HK1201067A1 (en) | Sialic acid analogs | |
| SMT201600199B (en) | PERFECTIONS RELATED TO PUMPS FOR PENIS | |
| FR2974862B1 (en) | GEAR PUMP | |
| HK1199033A1 (en) | Sulfonic acid salts of heterocyclylamide-substituted imidazoles | |
| SMT201600071B (en) | PYRROLIDINE-3-ILACETIC ACID DERIVATIVE | |
| BR112013030888A2 (en) | method to produce a compound. | |
| BR112013015002A2 (en) | method to obtain a compound | |
| BR112014025158A2 (en) | method to produce a compound. | |
| CO6811871A2 (en) | Process for the crystallization of a water soluble compound | |
| EP2768812A4 (en) | Acid addition salts of bosentan | |
| BR112013015003A2 (en) | method to obtain a compound | |
| AU2011200745B2 (en) | 4-hydroxybutyric acid analogs |